Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy
Accurate immune molecular typing is pivotal for screening out patients with colon adenocarcinoma (COAD) who may benefit from immunotherapy and whose tumor microenvironment (TME) was needed for reprogramming to beneficial immune-mediated responses. However, little is known about the immune characteri...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.934083/full |
| _version_ | 1828396949785542656 |
|---|---|
| author | Midie Xu Midie Xu Midie Xu Jinjia Chang Jinjia Chang Wenfeng Wang Xin Wang Xin Wang Xin Wang Xu Wang Xu Wang Xu Wang Weiwei Weng Weiwei Weng Weiwei Weng Cong Tan Cong Tan Cong Tan Meng Zhang Meng Zhang Meng Zhang Shujuan Ni Shujuan Ni Shujuan Ni Lei Wang Lei Wang Lei Wang Zhaohui Huang Zhenzhong Deng Wenhua Li Wenhua Li Dan Huang Dan Huang Dan Huang Weiqi Sheng Weiqi Sheng Weiqi Sheng |
| author_facet | Midie Xu Midie Xu Midie Xu Jinjia Chang Jinjia Chang Wenfeng Wang Xin Wang Xin Wang Xin Wang Xu Wang Xu Wang Xu Wang Weiwei Weng Weiwei Weng Weiwei Weng Cong Tan Cong Tan Cong Tan Meng Zhang Meng Zhang Meng Zhang Shujuan Ni Shujuan Ni Shujuan Ni Lei Wang Lei Wang Lei Wang Zhaohui Huang Zhenzhong Deng Wenhua Li Wenhua Li Dan Huang Dan Huang Dan Huang Weiqi Sheng Weiqi Sheng Weiqi Sheng |
| author_sort | Midie Xu |
| collection | DOAJ |
| description | Accurate immune molecular typing is pivotal for screening out patients with colon adenocarcinoma (COAD) who may benefit from immunotherapy and whose tumor microenvironment (TME) was needed for reprogramming to beneficial immune-mediated responses. However, little is known about the immune characteristic of COAD. Here, by calculating the enrichment score of immune characteristics in three online COAD datasets (TCGA-COAD, GSE39582, and GSE17538), we identified 17 prognostic-related immune characteristics that overlapped in at least two datasets. We determined that COADs could be stratified into three immune subtypes (IS1–IS3), based on consensus clustering of these 17 immune characteristics. Each of the three ISs was associated with distinct clinicopathological characteristics, genetic aberrations, tumor-infiltrating immune cell composition, immunophenotyping (immune “hot” and immune “cold”), and cytokine profiles, as well as different clinical outcomes and immunotherapy/therapeutic response. Patients with the IS1 tumor had high immune infiltration but immunosuppressive phenotype, IS3 tumor is an immune “hot” phenotype, whereas those with the IS2 tumor had an immune “cold” phenotype. We further verified the distinct immune phenotype of IS1 and IS3 by an in-house COAD cohort. We propose that the immune subtyping can be utilized to identify COAD patients who will be affected by the tumor immune microenvironment. Furthermore, the ISs may provide a guide for personalized cancer immunotherapy and for tumor prognosis. |
| first_indexed | 2024-12-10T08:38:21Z |
| format | Article |
| id | doaj.art-a95f88b798b44c7488fbabebf03e342b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-10T08:38:21Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a95f88b798b44c7488fbabebf03e342b2022-12-22T01:55:55ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-07-011310.3389/fimmu.2022.934083934083Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapyMidie Xu0Midie Xu1Midie Xu2Jinjia Chang3Jinjia Chang4Wenfeng Wang5Xin Wang6Xin Wang7Xin Wang8Xu Wang9Xu Wang10Xu Wang11Weiwei Weng12Weiwei Weng13Weiwei Weng14Cong Tan15Cong Tan16Cong Tan17Meng Zhang18Meng Zhang19Meng Zhang20Shujuan Ni21Shujuan Ni22Shujuan Ni23Lei Wang24Lei Wang25Lei Wang26Zhaohui Huang27Zhenzhong Deng28Wenhua Li29Wenhua Li30Dan Huang31Dan Huang32Dan Huang33Weiqi Sheng34Weiqi Sheng35Weiqi Sheng36Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaInstitute of Pathology, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, ChinaShanghai Urological Cancer Institute, Cancer Institute, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaInstitute of Pathology, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaInstitute of Pathology, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaInstitute of Pathology, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaInstitute of Pathology, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaInstitute of Pathology, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaInstitute of Pathology, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaInstitute of Pathology, Fudan University, Shanghai, ChinaWuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, ChinaDepartment of Oncology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaInstitute of Pathology, Fudan University, Shanghai, ChinaDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical college, Fudan University, Shanghai, ChinaInstitute of Pathology, Fudan University, Shanghai, ChinaAccurate immune molecular typing is pivotal for screening out patients with colon adenocarcinoma (COAD) who may benefit from immunotherapy and whose tumor microenvironment (TME) was needed for reprogramming to beneficial immune-mediated responses. However, little is known about the immune characteristic of COAD. Here, by calculating the enrichment score of immune characteristics in three online COAD datasets (TCGA-COAD, GSE39582, and GSE17538), we identified 17 prognostic-related immune characteristics that overlapped in at least two datasets. We determined that COADs could be stratified into three immune subtypes (IS1–IS3), based on consensus clustering of these 17 immune characteristics. Each of the three ISs was associated with distinct clinicopathological characteristics, genetic aberrations, tumor-infiltrating immune cell composition, immunophenotyping (immune “hot” and immune “cold”), and cytokine profiles, as well as different clinical outcomes and immunotherapy/therapeutic response. Patients with the IS1 tumor had high immune infiltration but immunosuppressive phenotype, IS3 tumor is an immune “hot” phenotype, whereas those with the IS2 tumor had an immune “cold” phenotype. We further verified the distinct immune phenotype of IS1 and IS3 by an in-house COAD cohort. We propose that the immune subtyping can be utilized to identify COAD patients who will be affected by the tumor immune microenvironment. Furthermore, the ISs may provide a guide for personalized cancer immunotherapy and for tumor prognosis.https://www.frontiersin.org/articles/10.3389/fimmu.2022.934083/fullcolon adenocarcinomaimmune characteristicsprognosistherapy responseimmune subtype analysis |
| spellingShingle | Midie Xu Midie Xu Midie Xu Jinjia Chang Jinjia Chang Wenfeng Wang Xin Wang Xin Wang Xin Wang Xu Wang Xu Wang Xu Wang Weiwei Weng Weiwei Weng Weiwei Weng Cong Tan Cong Tan Cong Tan Meng Zhang Meng Zhang Meng Zhang Shujuan Ni Shujuan Ni Shujuan Ni Lei Wang Lei Wang Lei Wang Zhaohui Huang Zhenzhong Deng Wenhua Li Wenhua Li Dan Huang Dan Huang Dan Huang Weiqi Sheng Weiqi Sheng Weiqi Sheng Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy Frontiers in Immunology colon adenocarcinoma immune characteristics prognosis therapy response immune subtype analysis |
| title | Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy |
| title_full | Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy |
| title_fullStr | Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy |
| title_full_unstemmed | Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy |
| title_short | Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy |
| title_sort | classification of colon adenocarcinoma based on immunological characterizations implications for prognosis and immunotherapy |
| topic | colon adenocarcinoma immune characteristics prognosis therapy response immune subtype analysis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.934083/full |
| work_keys_str_mv | AT midiexu classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT midiexu classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT midiexu classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT jinjiachang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT jinjiachang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT wenfengwang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT xinwang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT xinwang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT xinwang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT xuwang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT xuwang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT xuwang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT weiweiweng classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT weiweiweng classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT weiweiweng classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT congtan classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT congtan classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT congtan classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT mengzhang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT mengzhang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT mengzhang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT shujuanni classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT shujuanni classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT shujuanni classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT leiwang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT leiwang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT leiwang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT zhaohuihuang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT zhenzhongdeng classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT wenhuali classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT wenhuali classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT danhuang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT danhuang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT danhuang classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT weiqisheng classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT weiqisheng classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy AT weiqisheng classificationofcolonadenocarcinomabasedonimmunologicalcharacterizationsimplicationsforprognosisandimmunotherapy |